[go: up one dir, main page]

MX2018003023A - Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. - Google Patents

Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Info

Publication number
MX2018003023A
MX2018003023A MX2018003023A MX2018003023A MX2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A
Authority
MX
Mexico
Prior art keywords
patient population
methods
treatment
particular patient
neurodegenerative disorders
Prior art date
Application number
MX2018003023A
Other languages
English (en)
Other versions
MX392677B (es
Inventor
Abushakra Susan
Kocis Petr
Tolar Martin
Hey John
Power Aidan
YU Jeremy
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018003023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2018003023A publication Critical patent/MX2018003023A/es
Publication of MX392677B publication Critical patent/MX392677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aquí se describen métodos para tratar, mejorar y/o prevenir la enfermedad de Alzheimer en una población de pacientes específica utilizando tramiprosato, ácido valil-3-amino-1-propansulfónico o una sal farmacéuticamente aceptable del mismo basado en una combinación de estado APOE4 y gravedad de la enfermedad.
MX2018003023A 2015-09-10 2016-09-09 Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. MX392677B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
MX2018003023A true MX2018003023A (es) 2018-06-06
MX392677B MX392677B (es) 2025-03-24

Family

ID=58240195

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003023A MX392677B (es) 2015-09-10 2016-09-09 Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
MX2022003128A MX2022003128A (es) 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003128A MX2022003128A (es) 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Country Status (21)

Country Link
US (3) US11191742B2 (es)
EP (2) EP3347002B1 (es)
JP (4) JP6789579B2 (es)
KR (2) KR102547164B1 (es)
CN (3) CN116712422A (es)
AU (1) AU2016319107B2 (es)
CA (1) CA2997376C (es)
DK (1) DK3347002T3 (es)
ES (1) ES2952727T3 (es)
FI (1) FI3347002T3 (es)
HR (1) HRP20230809T1 (es)
HU (1) HUE062511T2 (es)
LT (1) LT3347002T (es)
MD (1) MD3347002T2 (es)
MX (2) MX392677B (es)
PL (1) PL3347002T3 (es)
PT (1) PT3347002T (es)
RS (1) RS64481B1 (es)
SI (1) SI3347002T1 (es)
SM (1) SMT202300250T1 (es)
WO (1) WO2017044840A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN112867485A (zh) * 2018-08-01 2021-05-28 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
JP7466520B2 (ja) * 2018-08-01 2024-04-12 アルツェオン・インコーポレーテッド 神経変性障害を治療するためのスルホプロパン酸誘導体
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
WO2020257159A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20240116529A (ko) * 2021-12-09 2024-07-29 알제온, 인크. 알츠하이머병 치료에 사용하기 위한 alz-801
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE625212T1 (de) 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
ES2967330T3 (es) 2006-10-12 2024-04-29 Bellus Health Inc Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
WO2012024616A1 (en) * 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
EP3718563A1 (en) * 2014-02-08 2020-10-07 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Also Published As

Publication number Publication date
KR20220042480A (ko) 2022-04-05
FI3347002T3 (fi) 2023-08-10
US20220096406A1 (en) 2022-03-31
AU2016319107B2 (en) 2021-02-25
KR102547164B1 (ko) 2023-06-22
US11191742B2 (en) 2021-12-07
CN116712423A (zh) 2023-09-08
AU2016319107A1 (en) 2018-03-22
CN108289870A (zh) 2018-07-17
EP3347002A4 (en) 2019-04-24
KR20180051561A (ko) 2018-05-16
KR102412997B1 (ko) 2022-06-23
JP7128536B2 (ja) 2022-08-31
JP6789579B2 (ja) 2020-11-25
CA2997376C (en) 2024-05-14
WO2017044840A1 (en) 2017-03-16
JP2018526407A (ja) 2018-09-13
SMT202300250T1 (it) 2023-09-06
SI3347002T1 (sl) 2023-12-29
EP3347002B1 (en) 2023-06-07
PL3347002T3 (pl) 2023-11-13
LT3347002T (lt) 2023-09-11
EP3347002A1 (en) 2018-07-18
CN116712422A (zh) 2023-09-08
RS64481B1 (sr) 2023-09-29
HUE062511T2 (hu) 2023-11-28
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
JP2022145949A (ja) 2022-10-04
HK1257874A1 (en) 2019-11-01
EP4275750A3 (en) 2024-01-17
MD3347002T2 (ro) 2023-10-31
DK3347002T3 (da) 2023-08-14
HRP20230809T1 (hr) 2023-10-27
ES2952727T3 (es) 2023-11-03
MX2022003128A (es) 2022-08-02
MX392677B (es) 2025-03-24
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
PT3347002T (pt) 2023-07-27
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
MX2018003023A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2024010140A (es) Nuevos metodos.
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
MX385332B (es) Moduladores de ror-gamma.
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
EA201890111A1 (ru) Замещенные производные оксопиридина
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX384429B (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
WO2015143447A3 (en) Methods for treating neurological disorders
MX378940B (es) Trastornos neurodegenerativos.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.
LT3458045T (lt) Ebselenas, skirtas naudoti menjero ligos gydymui
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
MX2019001804A (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
WO2016182812A8 (en) Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos
MX2017006063A (es) Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal.